aTyr Pharma's lung disease drug misses main goal in late-stage trial

Core Insights - aTyr Pharma's experimental drug did not achieve its primary endpoint in a late-stage study for pulmonary sarcoidosis, indicating a setback in its development pipeline [1] Company Summary - The drug was being tested in patients with pulmonary sarcoidosis, a type of lung disease [1] - The failure to meet the main goal suggests potential challenges for aTyr Pharma in advancing this treatment [1]